Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
AMN Healthcare (AMN) Boosts Service Portfolio With New Offering
by Zacks Equity Research
AMN Healthcare's (AMN) new pledge to provide support minority-owned businesses, thereby helping them to thrive.
Hill-Rom (HRC) FLC Growth Continues, Surgical Arm Stays Dull
by Zacks Equity Research
Within Front Line Care (FLC), Hill-Rom (HRC) registers growth in vital signs monitoring, blood pressure and thermometry as well as the completion of the U.S. stockpile order for noninvasive ventilators.
Boston Scientific (BSX) to Divest BTG's Non-MedTech Arm
by Zacks Equity Research
BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.
Align Technology (ALGN) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Align Technology (ALGN) is optimistic about maintaining a robust product portfolio along with strength in its international business.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Baxter (BAX) Announces Site Expansion to Improve Patient Care
by Zacks Equity Research
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Here's Why You Should Invest in Syneos Health (SYNH) Now
by Zacks Equity Research
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Why You Should Add Merit Medical (MMSI) to Your Portfolio
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, courtesy of its solid prospects.
Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis
by Zacks Equity Research
Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
LabCorp (LH) Expands in New Jersey With Clinical Trial Deal
by Zacks Equity Research
LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter performance is likely to reflect better performance by CVI and CSI.
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
by Zacks Equity Research
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
Hologic (HOLX) Gets Additional FDA Nod, to Aid HIV Testing
by Zacks Equity Research
Additional FDA approval for Hologic's (HOLX) molecular diagnostic test is expected to aid in the diagnosis of HIV infection.
Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts
by Zacks Equity Research
Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
Enjoy Thanksgiving with a Wall Street Bonanza
by Nalak Das
It will be prudent to invest in large-cap stocks with a favorable Zacks Rank that are members of any of the three large-cap indexes. These are DHR, UPS, NVDA, MSFT, TGT, TMO, DE, FDX.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Q3 Earnings Scorecard and Analyst Reports for Tesla, JPMorgan & Comcast
by Sheraz Mian
We have provided a real-time scorecard of the Q3 earnings season, in addition to featuring new research reports on Tesla (TSLA), JPMorgan Chase (JPM) and Comcast (CMCSA).
Zacks.com featured highlights include: TeleTech, Thermo Fisher, Best Buy, ParkerHannifin and Nu Skin
by Zacks Equity Research
Zacks.com featured highlights include: TeleTech, Thermo Fisher, Best Buy, ParkerHannifin and Nu Skin
Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm
by Zacks Equity Research
Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.